Diagnostics technology company LipoScience, in the midst of plans to go public as it builds commercialization efforts for its test for cardiovascular disease, now has a new chief medical officer.
Dr. Robert Honigberg was named CMO and vice president of medical affairs for the Raleigh, North Carolina company. LipoScience has developed a blood test that gauges a person’s risk of cardiovascular disease. The company is positioning its test as a more accurate alternative to existing cholesterol tests.
The LipoScience diagnostic uses nuclear magnetic resonance technology, or NMR, to measure the number of low density lipoprotein particles (LDL-P) in a blood sample. The U.S. Food and Drug Administration granted LipoScience 510 (k) clearance on the technology in 2008. LipoScience filed for an initial public stock offering in June, stating that proceeds from the $86 million offering would be used to expand sales and marketing efforts and for continued R&D on the NMR diagnostic.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Honigberg will oversee clinical trials work for LipoScience’s technologies. He’ll also have an outreach role at the company seeking partnerships and building relationships with medical societies, advocacy organizations and academics as well as health plans. LipoScience’s NMR test is already covered by some insurance companies.
Honigberg comes to LipoScience from URAC, a Washington, D.C.-based healthcare accreditation commission. His experience also includes serving as CMO for GE Healthcare and CMO of Ethicon Endo-Surgery, a Johnson & Johnson (NYSE:JNJ) company. He has also worked for Ortho Biotech and Schering Plough.
